Clinical Trial

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.
Protocol Amendment History 16 changes
notable Trial sites expanded: 195 -> 198 locations 2026-08-08
notable Trial sites expanded: 192 -> 195 locations 2026-07-21
notable Trial sites expanded: 186 -> 192 locations 2026-07-11
notable Trial sites expanded: 181 -> 186 locations 2026-07-07
notable Trial sites expanded: 175 -> 181 locations 2026-06-13
notable Trial sites expanded: 170 -> 175 locations 2026-06-09
notable Trial sites expanded: 160 -> 170 locations 2026-05-30
notable Trial sites expanded: 156 -> 160 locations 2026-05-27
notable Trial sites expanded: 153 -> 156 locations 2026-05-19
notable Trial sites expanded: 149 -> 153 locations 2026-05-12
notable Trial sites expanded: 145 -> 149 locations 2026-05-05
notable Trial sites expanded: 134 -> 145 locations 2026-04-29
notable Trial sites expanded: 122 -> 134 locations 2026-04-21
notable Trial sites expanded: 116 -> 122 locations 2026-04-14
notable Trial sites expanded: 110 -> 116 locations 2026-04-04
notable Trial sites expanded: 104 -> 110 locations 2026-04-01
Trial Details
NCT Number NCT07190248
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Non-small Cell Lung Cancer
Enrollment 675 participants
Start Date 2025-10-08
Primary Completion 2029-12-07 (estimated)
Study Completion 2032-08-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-07